Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001042641 | SCV001206337 | uncertain significance | Left ventricular noncompaction 8 | 2024-07-22 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 278 of the PRDM16 protein (p.Gly278Ser). This variant is present in population databases (rs375316181, gnomAD 0.06%), and has an allele count higher than expected for a pathogenic variant. This variant has not been reported in the literature in individuals affected with PRDM16-related conditions. ClinVar contains an entry for this variant (Variation ID: 840605). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV002255608 | SCV002526515 | uncertain significance | not provided | 2022-02-09 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 26582918) |
Fulgent Genetics, |
RCV001042641 | SCV002785902 | uncertain significance | Left ventricular noncompaction 8 | 2021-10-08 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004649413 | SCV005151970 | uncertain significance | Inborn genetic diseases | 2024-04-29 | criteria provided, single submitter | clinical testing | The c.832G>A (p.G278S) alteration is located in exon 6 (coding exon 6) of the PRDM16 gene. This alteration results from a G to A substitution at nucleotide position 832, causing the glycine (G) at amino acid position 278 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Mayo Clinic Laboratories, |
RCV002255608 | SCV005412305 | uncertain significance | not provided | 2024-08-21 | criteria provided, single submitter | clinical testing | BP4 |